Filter zurücksetzen
Stichworte
Lymphom, B-Zell- ×
Zeige mehr Stichworte
Inhaltsverzeichnis
  1. 1. Klinische Studie
  2. 2. Routinedokumentation
  3. 3. Register-/Kohortenstudien
  4. 4. Qualitätssicherung
  5. 5. Datenstandard
  6. 6. Patientenfragebogen
  7. 7. Medizinische Fachrichtung
    1. 7.1. Anästhesie
    1. 7.2. Dermatologie
    1. 7.3. HNO
    1. 7.4. Geriatrie
    1. 7.5. Gynäkologie/Geburtshilfe
    1. 7.6. Innere Medizin
      1. Hämatologie
      1. Infektiologie
      1. Kardiologie/Angiologie
      1. Pneumologie
      1. Gastroenterologie
      1. Nephrologie
      1. Endokrinologie/Stoffwechsel
      1. Rheumatologie
    1. 7.7. Neurologie
    1. 7.8. Augenheilkunde
    1. 7.9. Palliativmedizin
    1. 7.10. Pathologie/Rechtsmedizin
    1. 7.11. Kinderheilkunde
    1. 7.12. Psychiatrie/Psychosomatik
    1. 7.13. Radiologie
    1. 7.14. Chirurgie
      1. Allgemein-/Viszeralchirurgie
      1. Neurochirurgie
      1. Plastische Chirurgie
      1. Herz-/Thoraxchirurgie
      1. Unfallchirurgie/Orthopädie
      1. Gefäßchirurgie
    1. 7.15. Urologie
    1. 7.16. Zahnmedizin/MKG
Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

72 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

Eligibility B-cell Non Hodgkin Lymphoma NCT01516580

- 19.08.19 - 1 Formular, 2 Itemgruppen, 18 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01516580

Eligibility Renal Cell Carcinoma and B-Cell Non-Hodgkin's Lymphoma NCT00944905

- 27.08.18 - 1 Formular, 2 Itemgruppen, 15 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL); ODM derived from: https://clinicaltrials.gov/show/NCT00944905

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Patient Enrollment

- 10.07.18 - 1 Formular, 11 Itemgruppen, 39 Datenelemente, 1 Sprache
Itemgruppen: Demographics, Lymphoid Neoplasms; Inclusion Criteria, CD20 antigen; Inclusion Criteria, Prior chemotherapy; Inclusion Criteria, Karnofsky Performance Status; Survival time, Anticipated; Inclusion Criteria, ANC; Platelet Count; Inclusion Criteria, Renal function; Hepatic function; Inclusion Criteria, Bi-dimensionally measured disease; Inclusion Criteria, Age; Inclusion Criteria, Informed Consent; Inclusion Criteria, Exclusion criteria
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

AMC-075 Lymphoma Disease Activity and Measurement Form (L01)

- 09.10.17 - 1 Formular, 5 Itemgruppen, 17 Datenelemente, 1 Sprache
Itemgruppen: Header - Lymphoma Disease Activity and Measurement Form, Reporting Period, Nodal Involvement Evaluation, Extra Nodal Involvement Evaluation, Comments
AMC-075 Lymphoma Disease Activity and Measurement Form (L01) Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With Previously Untreated HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9F166B5D-4C13-06F1-E040-BB89AD434FAE

AMC-075 HIV T-Cell Laboratory Values Form (F24)

- 24.08.17 - 1 Formular, 2 Itemgruppen, 11 Datenelemente, 1 Sprache
Itemgruppen: Header - HIV T-Cell Laboratory Values Form, T-Cell Laboratory Values
AMC-075 HIV T-Cell Laboratory Values Form (F24) Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With Previously Untreated HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9F15665C-2E3D-498C-E040-BB89AD433080

Interim-PET and Randomisation PETAL Study NCT00554164 - Interim-PET and Randomisation

- 20.09.21 - 1 Formular, 4 Itemgruppen, 15 Datenelemente, 2 Sprachen
Itemgruppen: Interim-PET und Randomisation, PET, Stratification criteria, Footer module
Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (PETAL-Studie) Universitätsklinikum Essen (UK Essen) EudraCT-Nummer: 2006-001641-33 NCT00554164

Eligibility Mature B-Cell Lymphoma NCT01046825

- 27.09.21 - 1 Formular, 2 Itemgruppen, 25 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Mature B-Cell Lymphoma And Leukemia Study III; ODM derived from: https://clinicaltrials.gov/show/NCT01046825

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - History of Lymphoma

- 20.09.21 - 1 Formular, 5 Itemgruppen, 21 Datenelemente, 1 Sprache
Itemgruppen: Administrative Data, Cell Type, Grade, Extranodal Involvement at Enrollment, CD20 Reactivity
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Infusion Record - Therapy Dose - Day 7

- 06.08.18 - 1 Formular, 5 Itemgruppen, 32 Datenelemente, 1 Sprache
Itemgruppen: Administrative Data, Infusion, Vital signs, Adverse Experiences, Infusion; Patient compliance
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Infusion Record - Dosimetric Dose - Day 0

- 06.08.18 - 1 Formular, 4 Itemgruppen, 29 Datenelemente, 1 Sprache
Itemgruppen: Administrative Data, Infusion, Vital signs, Adverse Experiences
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Post Treatment Response - Follow-Up

- 25.07.18 - 1 Formular, 10 Itemgruppen, 39 Datenelemente, 1 Sprache
Itemgruppen: Administrative Data, Diagnostic Imaging, Head/Neck, Diagnostic Imaging; Chest, Diagnostic Imaging, Abdomen, Diagnostic Imaging, Pelvis, Diagnostic Imaging, Other, Bone Marrow Biopsy, Measurable Lymphoma Disease, Non-Measurable Disease, Response to treatment
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - HAMA Results

- 25.07.18 - 1 Formular, 2 Itemgruppen, 6 Datenelemente, 1 Sprache
Itemgruppen: Administrative Data, HAMA Results
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video